Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949]

  • Awaiting development
  • GID-TA11465
  • Expected publication date: TBC

NIHRIO BN: 34858-Isatuximab-Bortezomib-Lenalidomide-Dexamethasone-for-Multiple-Myeloma-V1.0-OCT2023-NON-CONF-.pdf (nihr.ac.uk)